Specific use-results survey to evaluate the safety and outcome of Pivlaz use in patients after aneurysmal subarachnoid hemorrhage treatment
Not Applicable
Recruiting
- Conditions
- Prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery
- Registration Number
- JPRN-UMIN000048297
- Lead Sponsor
- xera Pharma Japan Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety -Adverse events (AE) -Adverse drug reactions (ADR)
- Secondary Outcome Measures
Name Time Method Outcome Evaluate the Mortality/morbidity events -Death -New cerebral vasospasm -New cerebral vasospasm-related new cerebral infarction -New cerebral vasospasm-related delayed ischemic neurological deficit (DIND) Evaluation of prognosis -mRS -GOSE -MMSE-J